CStone Pharmaceuticals-B (09966): JSKN003 was approved by the US FDA to conduct a phase II clinical trial for the treatment of PROC regardless of HER2 expression level.

Wisdom Financial App News, Concord Medical-Jerry Pharmaceutical-B (09966) announced that JSKN003 has been approved by the Food and Drug Administration (FDA) of the United States to conduct a Phase II clinical study (Study Number: JSKN003-202) in the United States. JSKN003-202 is a randomized, open-label, multicenter Phase II clinical study of JSKN003, used to treat platinum-resistant recurrent epithelial ovarian cancer, primary peritoneal cancer, or fallopian tube cancer (collectively referred to as platinum-resistant ovarian cancer, PROC), regardless of human epidermal growth factor receptor 2 (HER2) expression levels. This clinical trial aims to assess the efficacy and safety of JSKN003 in the above-mentioned population and determine the recommended Phase III dose. The approval of JSKN003-202 by the US FDA is an important milestone for the company in promoting the global development of innovative pipelines, and will continue to enhance the company's core competitiveness in the field of anti-tumor treatment.